CISATRACURIUM BESYLATE INJECTION (PRESERVATIVE-FREE) SOLUTION

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

CISATRACURIUM (CISATRACURIUM BESYLATE)

Disponível em:

MYLAN PHARMACEUTICALS ULC

Código ATC:

M03AC11

DCI (Denominação Comum Internacional):

CISATRACURIUM

Dosagem:

2MG

Forma farmacêutica:

SOLUTION

Composição:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

Via de administração:

INTRAVENOUS

Unidades em pacote:

5ML

Tipo de prescrição:

Prescription

Área terapêutica:

NEUROMUSCULAR BLOCKING AGENTS

Resumo do produto:

Active ingredient group (AIG) number: 0133260001; AHFS:

Status de autorização:

CANCELLED PRE MARKET

Data de autorização:

2018-06-15

Características técnicas

_ _
_Page 1 of 30 _
_ _
PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION (PRESERVATIVE-FREE)
SOLUTION FOR INJECTION
2 MG/ML CISATRACURIUM (AS CISATRACURIUM BESYLATE)
5 ML SINGLE DOSE VIAL
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR
WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Preparation: August 18, 2014
Control No.: 176645
_ _
_Page 2 of 30 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
8
DRUG INTERACTIONS
............................................................................................................
9
DOSAGE AND ADMINISTRATION
......................................................................................
10
OVERDOSAGE
.........................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
16
STORAGE AND STABILITY
..................................................................................................
22
SPECIAL HANDLING INSTRUCTIONS
................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................